CCL22 and gastric cancer: In gastric cancer, miRNA-130a-5p can inhibit the activation of Wnt/β-catenin pathway by targeting CB1R, bind to CCL22 targets, and negatively regulate CCL22 protein expression levels, thereby exerting antitumor effects and inhibiting gastric cancer progression [20].